^
Association details:
| Biomarker: | ALK C1156Y + ALK G1202R |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | TPX-0131 (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Abstract 5226: TPX-0131: A next generation macrocyclic ALK inhibitor that overcomes ALK resistant mutations refractory to current approved ALK inhibitors
Published date:
05/15/2020
Excerpt:
Furthermore, TPX-0131 demonstrated antiproliferation IC50 values <2 nM in Ba/F3 cell models engineered with compound mutations including L1196M/G1202R, L1198F/G1202R, L1196M/L1198F, and C1156Y/G1202R, while lorlatinib and other ALK inhibitors are not active (IC50s >1 μM).
DOI:
10.1158/1538-7445.AM2020-5226
